Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the completion of the previously announced sale of AL102, and related drug candidate AL101, to Immunome, Inc. (Nasdaq: IMNM). As per the terms of the sale, Ayala received from Immunome $20 million in cash and 2,175,489 shares … …